Kolon Biotech, a subsidiary of Kolon Life Science, is set to expand its global partnerships by showcasing its capabilities in contract development and manufacturing organization (CDMO) for cell and gene therapies.
The company announced it will participate in the 'BioPlus-Interphex Korea 2026 (BIX 2026)' event, taking place from October 28 to 30 at Seoul COEX. During the event, Kolon Biotech will operate an independent booth in the CMO/CDMO zone, where it will introduce its CDMO services for advanced biopharmaceuticals, including cell therapies, genetically modified cell therapies, stem cell therapies, and exosome therapies. The company plans to hold business meetings with domestic and international biotech firms to explore new partnerships and collaboration opportunities.
Founded in 2020 as a specialized CDMO for cell and gene therapies, Kolon Biotech was established by spinning off the bio-manufacturing division of Kolon Life Science. The company operates a Good Manufacturing Practice (GMP) facility in Chungju, capable of producing both clinical trial materials and commercial products.
Kolon Biotech offers a comprehensive range of services throughout the drug development process, including process development, quality testing, GMP production, regulatory support, and storage and transportation. The Chungju Bio Plant 1 is responsible for clinical trial samples and initial commercial supply, while Bio Plant 2 handles large-scale commercial supply.
To ensure stable mass production of cells, the company is also focusing on expanding the use of automated systems and closed systems in its two-dimensional (2D) cell culture processes. This initiative aims to enhance productivity and strengthen cost competitiveness in manufacturing.
A representative from Kolon Biotech stated, "At BIX 2026, we will showcase our CDMO capabilities and seek new collaboration opportunities. We aim to continuously enhance our competitiveness as a professional and flexible CDMO partner that reliably supports our clients from drug candidate development to commercial production."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.